<DOC>
	<DOCNO>NCT00796562</DOCNO>
	<brief_summary>The purpose study see give high dose chemotherapy total body irradiation repeat high dose chemotherapy bone marrow transplant could reduce incidence graft rejection disease patient blood cancer</brief_summary>
	<brief_title>Safety Study Bone Marrow Transplant Using Mismatched Tissue Followed Chemotherapy</brief_title>
	<detailed_description>Allogeneic blood marrow transplantation ( alloBMT ) , follow either marrow-ablative nonmyeloablative conditioning , potentially curative treatment variety hematologic malignancy non-malignant hematologic disorder . Of potential source allograft , transplantation stem cell human leukocyte antigen ( HLA ) -matched sibling generally produce best overall outcome , i.e . overall progression-free survival . Unfortunately , third candidate alloBMT HLA-matched sibling . For patient lack HLA-matched sibling , three alternative source stem cell alloBMT : 1 ) volunteer unrelated donor ; 2 ) umbilical cord blood ; 3 ) partially HLA-mismatched , haploidentical , related donor . Since patient share exactly one HLA haplotype biological parent child half sibling , eligible haploidentical donor identify rapidly nearly case . However , haploidentical BMT associate significant risk graft rejection severe GVHD , manifestation excessive alloreactivity host donor T cell , respectively . The risk severe GVHD may reduce intensively condition recipient graft rigorously deplete mature T cell selectively deplete alloreactive T cell , risk serious infection death prolong immune compromise patient remain high . Cyclophosphamide ( Cy ) highly immunosuppressive antineoplastic agent establish role condition alloBMT . Typically , drug administer prior transplantation prevent graft rejection suppress host immune system . However , pre-transplantation conditioning Cy increase risk GVHD follow allogeneic T cell infusion mouse model . In contrast , administration properly time , high dose Cy BMT inhibit graft rejection GVHD .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Acute lymphocytic leukemia high risk CR1 Acute myeloid leukemia CR1 Therapyrelated AML RAEB &gt; 5 % &lt; 20 % bone marrow blast Chronic myelogenous leukemia beyond 1st chronic phase ; Patients blast crisis CMMoL JMML Chemotherapyresistant Hodgkins Lymphoma intermediate high grade NonHodgkins lymphoma ( Less PR standard salvage chemotherapy ) Mantle cell lymphoma : chemotherapy refractory ( Less PR standard salvage chemotherapy ) patient beyond CR1 chemosensitive disease Follicular Lymphoma , Grade 3 Transformed indolent lymphoma Poor cardiac function : leave ventricular ejection fraction &lt; 45 % determined MUGA ECHO . For pediatric patient LVEF &lt; 45 % shorten fraction normal limit age . Poor pulmonary function : FEV1 FVC &lt; 50 % predict patient receive thoracic mantle irradiation . For patient receive thoracic mantle irradiation , FEV1 FVC &lt; 70 % predict DLCO &lt; 50 predict . For child unable perform PFTs developmental stage pulse oximetry &lt; 85 % RA Poor liver function : bilirubin &gt; 2 mg/dl ( due hemolysis , Gilbert 's primary malignancy ) Poor renal function : Creatinine &gt; 2.0mg/dl creatinine clearance HIVpositive Positive leukocytotoxic crossmatch Women childbearing potential currently pregnant practice adequate contraception Uncontrolled viral , bacterial , fungal infection Patients symptom consistent RSV , influenza A , B , parainfluenza time enrollment assayed virus positive eligible trial longer symptomatic ( patient may continue assay positivity period time post resolution symptom secondary nature assay . Indolent lymphoma ( Follicular Grade 1 2 , marginal zone , chronic lymphocytic leukemia , small lymphocytic lymphoma , MALT )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Mismatched</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cellcept</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>TBI</keyword>
	<keyword>CMMOL</keyword>
	<keyword>CML</keyword>
	<keyword>JMML</keyword>
</DOC>